AFT PharmaceuticalsNZSE:AFT +0.27%96 PB Ratio is 3.50 as of Jun. 26, 2026, which is 64% below its 10-year median of 9.59. GuruFocus rates NZSE:AFT with a GF Score™ of 96/100 and a GF Value™ of NZ$4.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 73.64% on this metric.
The historical rank and industry rank for AFT Pharmaceuticals's PB Ratio or its related term are showing as below:
NZSE:AFT'
s PB Ratio Range Over the Past 10 Years
Min: 2.75 Med: 9.59 Max: 75
Current: 3.5
During the past 11 years, AFT Pharmaceuticals's highest PB Ratio was 75.00. The lowest was 2.75. And the median was 9.59.
NZSE:AFT's PB Ratio is ranked worse than 73.64% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NZSE:AFT: 3.50
During the past 12 months, AFT Pharmaceuticals's average Book Value Per Share Growth Rate was 13.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 23.20% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of AFT Pharmaceuticals was 118.40% per year. The lowest was -43.70% per year. And the median was 19.80% per year.
Back to Basics: PB Ratio
AFT Pharmaceuticals (NZSE:AFT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
AFT Pharmaceuticals PB Ratio Related Terms
AFT Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
AFT Pharmaceuticals (NZSE:AFT) has a PB Ratio of 3.50 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AFT Pharmaceuticals and its competitors. This is 64% below median its historical median of 9.59. Over the past decade, AFT Pharmaceuticals' PB Ratio has ranged from 2.75 to 75.00. According to the industry distribution chart, AFT Pharmaceuticals ranks #679 out of 922 companies in the Drug Manufacturers industry, placing it in the top 73.6%.
Is AFT Pharmaceuticals' PB Ratio too high?
AFT Pharmaceuticals' current PB Ratio of 3.50 is 64% below median its 10-year median of 9.59. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 75.00. The Drug Manufacturers industry median PB Ratio is 1.83. AFT Pharmaceuticals' value of 3.50 is 91.8% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #679 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #679 out of 922 companies for PB Ratio. This places AFT Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.83. AFT Pharmaceuticals' value of 3.50 is 91.8% above this benchmark. Historically, AFT Pharmaceuticals' own PB Ratio has ranged from 2.75 to 75.00 over the past decade. While the company's 10-year median is 9.59 vs. the industry median of 1.83, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current PB Ratio of 3.50 is 91.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current PB Ratio is 3.50, which is 64% below median its own 10-year median of 9.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$4.15, compared to a current price of NZ$3.68 — trading 11.3% below its estimated fair value. The current PB Ratio is 3.50, which is 64% below median its 10-year median of 9.59 and 91.8% above the Drug Manufacturers industry median of 1.83. AFT Pharmaceuticals' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current PB Ratio is 3.50 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.68 is trading 11.3% below its estimated GF Value™ of NZ$4.15.
GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NZSE:AFT:
PB Ratio: 3.50 (64% below median its 10-year median of 9.59)
GF Value™: NZ$4.15 vs. price of NZ$3.68 (11.3% below fair value)
Industry Position: 91.8% above the Drug Manufacturers median (#679 of 922)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
96GF Score
Get the complete analysis for NZSE:AFT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
